Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
NTRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$110.57 - $183.00
Previous CloseN/A
Volume352.74K
Average Volume (3M)1.54M
Market Cap
$22.30B
Enterprise Value$22.22B
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$196.13M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Nov 05, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding137,248,110
10 Day Avg. Volume1,288,653
30 Day Avg. Volume1,541,828
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue11.31
Enterprise Value/Gross Profit17.98
Enterprise Value/Ebitda-104.89
Forecast
1Y Price Target
$207.71Price Target Upside25.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe IMvigor011 trial results announced by Natera show statistically significant improvements in clinical outcomes for patients treated with atezolizumab when stratified with Signatera.
Market PositionThe strong evidence from the IMvigor011 trial and over 100 publications supports Signatera's dominant position in the MRD assay market.
Revenue GrowthNTRA raised its guidance to 28% revenue growth excluding true-ups, which should give additional comfort to investors despite aggressively expanding into other markets.
Bears Say
Guideline UpdateThe expected guideline update by NCCN in 2026 could significantly boost MRD uptake, particularly among community oncologists who treat the majority of cancer patients.
Operating ExpensesOperating expenses were higher than expected, which affected the EBITDA margin.
Natera News
NTRA FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was $110.57 and its highest was $183.00 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is $22.30B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Aug 07, 2025. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.615 by -$0.125.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.38.
How many shares outstanding does Natera have?
Natera has 137,248,110 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.615. Following the earnings report the stock price went up 7.705%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in NTRA
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$207.71 (25.35% Upside)
$207.71 (25.35% Upside)
Blogger Sentiment
Neutral
NTRA Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 285.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.40%
12-Months-Change
Fundamentals
Return on Equity
-24.32%
Trailing 12-Months
Asset Growth
15.83%
Trailing 12-Months
Company Description
Natera
Natera, Inc. is a leading genetic testing and diagnostics company that specializes in reproductive health, oncology, and organ transplantation. The company provides a range of genetic testing services, including non-invasive prenatal testing (NIPT), carrier screening, and tests for hereditary cancer risk. Natera's core products are designed to empower patients and healthcare providers with critical genetic information to make informed medical decisions.
NTRA Company Deck
NTRA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue and volume growth, particularly in the oncology segment with Signatera. The company raised its financial guidance significantly and introduced promising new products and AI initiatives. However, flat operating expenses and the exit from the paternity business were noted as areas of concern. Nevertheless, the positive aspects, including strong market performance and strategic innovations, dominate the outlook.View all NTRA earnings summariesNTRA Stock 12 Month Forecast
Average Price Target
$207.71
▲(25.35% Upside)
Technical Analysis
Ownership Overview
4.62% Insiders
29.87% Mutual Funds
26.47% Other Institutional Investors
22.97% Public Companies and
Individual Investors